TY - JOUR
T1 - Immunopathological effects of Agaricus blazei Murill polysaccharides against Schistosoma mansoni infection by Th1 and NK1 cells differentiation
AU - Lin, Ming Hong
AU - Lee, Kin Mu
AU - Hsu, Che Yuan
AU - Peng, Shih Yi
AU - Lin, Ching Nan
AU - Chen, Chin Chu
AU - Fan, Chia Kwung
AU - Cheng, Po Ching
N1 - Funding Information:
This study was partly supported by a grant MOST-106-2320-B-038-023 from Ministry of Science and Technology, Taipei, Taiwan .
Publisher Copyright:
© 2019
PY - 2019/8/1
Y1 - 2019/8/1
N2 - In this study, we examined the ability of A. blazei Murill polysaccharides (AB-PS) to activate the immune system in vivo and the protective activity exhibited against parasitic S. mansoni in the murine model. AB-PS treatment significantly reduced the worm and egg burden in infected BALB/c and C57BL/6 mice with dose- and time-dependent manners. Additionally, a dose- and time-dependent expression of IL-2, INF-γ, and TNF-α cytokines was also observed in both strains of mice treatments. Using T1/T2 doubly transgenic mice, we demonstrated that AB-PS-treated mice splenocytes initiated early differentiation of Th1 and NK1 cells, which was consistent with the reduction course of Schistosoma infection. Although AB-PS treatment enhanced the Th1 response, it did not suppress Th2 cell activity in treated mice. Histopathological data of the livers showed AB-PS treatment significantly attenuated the liver fibrosis induced by S. mansoni eggs. AB-PS augmented type-1 responses by inducing Th1 and NK1 cell differentiation to effectively decrease the infection rate of S. mansoni. Furthermore, AB-PS treatment may not only inhibit the schistosome infection, but also improving the pathological effects of granulomas formation. This study provides evidence for a novel therapeutic potential, by which A. blazei Murill may be used to treat or prevent schistosome infection.
AB - In this study, we examined the ability of A. blazei Murill polysaccharides (AB-PS) to activate the immune system in vivo and the protective activity exhibited against parasitic S. mansoni in the murine model. AB-PS treatment significantly reduced the worm and egg burden in infected BALB/c and C57BL/6 mice with dose- and time-dependent manners. Additionally, a dose- and time-dependent expression of IL-2, INF-γ, and TNF-α cytokines was also observed in both strains of mice treatments. Using T1/T2 doubly transgenic mice, we demonstrated that AB-PS-treated mice splenocytes initiated early differentiation of Th1 and NK1 cells, which was consistent with the reduction course of Schistosoma infection. Although AB-PS treatment enhanced the Th1 response, it did not suppress Th2 cell activity in treated mice. Histopathological data of the livers showed AB-PS treatment significantly attenuated the liver fibrosis induced by S. mansoni eggs. AB-PS augmented type-1 responses by inducing Th1 and NK1 cell differentiation to effectively decrease the infection rate of S. mansoni. Furthermore, AB-PS treatment may not only inhibit the schistosome infection, but also improving the pathological effects of granulomas formation. This study provides evidence for a novel therapeutic potential, by which A. blazei Murill may be used to treat or prevent schistosome infection.
KW - Agaricus blazei Murill polysaccharides
KW - Immunomodulation
KW - NK cell
KW - Schistosoma mansoni
KW - T1/T2 doubly transgenic mice
UR - http://www.scopus.com/inward/record.url?scp=85066499446&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066499446&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2019.05.045
DO - 10.1016/j.intimp.2019.05.045
M3 - Article
AN - SCOPUS:85066499446
SN - 1567-5769
VL - 73
SP - 502
EP - 514
JO - International Immunopharmacology
JF - International Immunopharmacology
ER -